Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for INZY
| Stock Name | Inozyme Pharma Inc |
| Ticker | INZY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US45790W1080 |
Show aggregate INZY holdings
News associated with INZY
- Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Hold” by Brokerages
- Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among […] - 2025-07-29 02:14:51
- OneDigital Investment Advisors LLC Raises Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)
- OneDigital Investment Advisors LLC grew its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) by 58.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,000 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. OneDigital Investment […] - 2025-07-14 05:02:53
- Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $11.75 Average Price Target from Analysts
- Shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) have earned a consensus rating of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month […] - 2025-07-07 02:06:55
- Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $11.75
- Shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) have been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […] - 2025-06-12 02:13:05
- Deutsche Bank AG Increases Position in Inozyme Pharma, Inc. (NASDAQ:INZY)
- Deutsche Bank AG grew its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) by 29.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 40,215 shares of the company’s stock after acquiring an additional 9,055 shares during the period. Deutsche Bank AG’s […] - 2025-06-04 04:44:53
- D. E. Shaw & Co. Inc. Makes New $49,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)
- D. E. Shaw & Co. Inc. bought a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 17,813 shares of the company’s stock, valued at approximately $49,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes […] - 2025-05-29 05:36:54
- Graham Capital Management L.P. Invests $33,000 in Inozyme Pharma, Inc. (NASDAQ:INZY)
- Graham Capital Management L.P. acquired a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,044 shares of the company’s stock, valued at approximately $33,000. Several other institutional investors and hedge funds have […] - 2025-05-20 05:09:21
- Inozyme Pharma (NASDAQ:INZY) Downgraded to “Hold” Rating by Wedbush
- Wedbush cut shares of Inozyme Pharma (NASDAQ:INZY – Free Report) from a strong-buy rating to a hold rating in a research note released on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) […] - 2025-05-19 02:24:52
- Pre-Market Most Active for May 16, 2025 : TSLL, INZY, NVDA, SQQQ, ACHR, CABA, TQQQ, NVO, SPCE, UNH, QBTS, NIO
- The NASDAQ 100 Pre-Market Indicator is up 57.92 to 21,393.74. The total Pre-Market volume is currently 272,014,558 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.43 at $15.25, with 15,512,189 sha - 2025-05-16 09:28:53
- BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash
- (RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in cash. - 2025-05-16 08:51:10
- Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages
- Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the […] - 2025-05-15 02:37:05
- Raymond James Financial Inc. Buys Shares of 74,165 Inozyme Pharma, Inc. (NASDAQ:INZY)
- Raymond James Financial Inc. bought a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 74,165 shares of the company’s stock, valued at approximately $205,000. Several other institutional investors and hedge funds have also […] - 2025-05-13 04:18:47
- XTX Topco Ltd Makes New Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)
- XTX Topco Ltd bought a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 31,737 shares of the company’s stock, valued at approximately $88,000. Several other hedge funds […] - 2025-05-01 05:24:55
- Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price
- Inozyme Pharma (NASDAQ:INZY – Get Free Report) had its price target lowered by equities researchers at Piper Sandler from $30.00 to $23.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Several other analysts have also issued reports on INZY. Wells Fargo & Company decreased their price […] - 2025-03-13 06:46:57
- Inozyme Pharma (NASDAQ:INZY) Receives Buy Rating from HC Wainwright
- Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the stock. Several other research firms have also commented on INZY. Wedbush reaffirmed an “outperform” rating and set a $7.00 […] - 2025-03-13 04:41:03
- Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC
- Inozyme Pharma (NASDAQ:INZY – Free Report) had its price target trimmed by Needham & Company LLC from $23.00 to $15.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other research analysts have also recently commented on INZY. Raymond James began coverage on […] - 2025-03-12 05:08:48
- Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY)
- Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $7.00 price objective on the stock, down from their previous price objective of $12.00. Several other analysts have also issued reports on the […] - 2025-03-12 04:00:48
- Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Target Price at $18.33
- Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has earned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the […] - 2025-03-04 04:00:51
- Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus Price Target from Brokerages
- Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock […] - 2025-02-07 04:12:55
- China Universal Asset Management Co. Ltd. Invests $38,000 in Inozyme Pharma, Inc. (NASDAQ:INZY)
- China Universal Asset Management Co. Ltd. bought a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,621 shares of the company’s stock, valued at approximately $38,000. […] - 2025-02-05 06:46:52
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) INZY holdings
| Date | Number of INZY Shares Held | Base Market Value of INZY Shares | Local Market Value of INZY Shares | Change in INZY Shares Held | Change in INZY Base Value | Current Price per INZY Share Held | Previous Price per INZY Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of INZY by Blackrock for IE00BYXG2H39
Show aggregate share trades of INZY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-06-25 | BUY | 210 | | | 3.990* | | 1.88 |
| 2025-06-11 | BUY | 210 | | | 3.970* | | 1.69 |
| 2025-06-10 | BUY | 210 | | | 3.980* | | 1.67 |
| 2025-06-04 | SELL | -105 | | | 3.980* | | 1.58  Profit of 166 on sale |
| 2025-04-23 | BUY | 105 | | | 0.981* | | 1.25 |
| 2025-04-10 | SELL | -840 | | | 0.881* | | 1.29 Profit of 1,084 on sale |
| 2025-04-08 | SELL | -105 | | | 0.855* | | 1.30 Profit of 137 on sale |
| 2025-04-07 | SELL | -105 | | | 0.904* | | 1.31 Profit of 138 on sale |
| 2025-04-04 | SELL | -525 | | | 0.821* | | 1.32 Profit of 692 on sale |
| 2025-04-01 | BUY | 420 | | | 0.870* | | 1.33 |
| 2025-03-31 | SELL | -315 | | | 0.910* | | 1.34 Profit of 422 on sale |
| 2025-03-14 | SELL | -1,680 | | | 1.000* | | 1.42 Profit of 2,388 on sale |
| 2025-03-07 | SELL | -210 | | | 1.150* | | 1.46 Profit of 307 on sale |
| 2025-03-04 | SELL | -106 | | | 1.120* | | 1.48 Profit of 157 on sale |
| 2025-02-25 | BUY | 210 | | | 1.190* | | 1.53 |
| 2025-02-19 | SELL | -105 | | | 1.310* | | 1.56 Profit of 164 on sale |
| 2025-02-13 | BUY | 315 | | | 1.350* | | 1.59 |
| 2025-02-12 | BUY | 105 | | | 1.350* | | 1.60 |
| 2025-02-11 | BUY | 420 | | | 1.290* | | 1.61 |
| 2025-01-17 | BUY | 420 | | | 1.360* | | 2.05 |
| 2025-01-16 | BUY | 420 | | | 1.360* | | 2.15 |
| 2025-01-10 | SELL | -210 | | | 1.995* | | 2.82 Profit of 592 on sale |
| 2025-01-08 | SELL | -420 | | | 2.800* | | 2.85 Profit of 1,197 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of INZY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-06-30 | 303,169 | 0 | 523,554 | 57.9% |
| 2025-06-27 | 177,651 | 3 | 361,007 | 49.2% |
| 2025-06-26 | 52,982 | 0 | 109,881 | 48.2% |
| 2025-06-25 | 207,533 | 0 | 373,467 | 55.6% |
| 2025-06-24 | 215,494 | 4,000 | 494,292 | 43.6% |
| 2025-06-23 | 100,053 | 0 | 296,314 | 33.8% |
| 2025-06-20 | 52,276 | 0 | 400,090 | 13.1% |
| 2025-06-18 | 120,880 | 43,183 | 420,020 | 28.8% |
| 2025-06-17 | 113,968 | 0 | 176,146 | 64.7% |
| 2025-06-16 | 99,192 | 0 | 273,896 | 36.2% |
| 2025-06-13 | 105,410 | 17,478 | 203,528 | 51.8% |
| 2025-06-12 | 61,108 | 4,184 | 118,267 | 51.7% |
| 2025-06-11 | 118,298 | 0 | 209,225 | 56.5% |
| 2025-06-10 | 145,311 | 0 | 385,710 | 37.7% |
| 2025-06-09 | 237,667 | 0 | 381,515 | 62.3% |
| 2025-06-06 | 47,562 | 0 | 89,241 | 53.3% |
| 2025-06-05 | 93,110 | 0 | 213,823 | 43.5% |
| 2025-06-04 | 296,424 | 1,000 | 567,448 | 52.2% |
| 2025-06-03 | 83,956 | 1,000 | 267,893 | 31.3% |
| 2025-06-02 | 383,275 | 0 | 830,838 | 46.1% |
| 2025-05-30 | 77,737 | 0 | 363,667 | 21.4% |
| 2025-05-29 | 1,107,244 | 1,257 | 3,011,345 | 36.8% |
| 2025-05-28 | 864,517 | 6,000 | 3,811,804 | 22.7% |
| 2025-05-27 | 314,791 | 120,555 | 561,075 | 56.1% |
| 2025-05-23 | 204,459 | 0 | 481,822 | 42.4% |
| 2025-05-22 | 230,583 | 400 | 422,306 | 54.6% |
| 2025-05-21 | 411,479 | 0 | 736,753 | 55.9% |
| 2025-05-20 | 375,766 | 0 | 3,633,797 | 10.3% |
| 2025-05-19 | 1,801,238 | 856 | 3,184,777 | 56.6% |
| 2025-05-16 | 7,263,502 | 83,396 | 19,208,975 | 37.8% |
| 2025-05-15 | 1,083,399 | 13,644 | 1,954,378 | 55.4% |
| 2025-05-14 | 958,464 | 144,550 | 2,164,376 | 44.3% |
| 2025-05-13 | 331,049 | 18,266 | 528,283 | 62.7% |
| 2025-05-12 | 158,699 | 700 | 307,018 | 51.7% |
| 2025-05-09 | 166,966 | 11,342 | 321,823 | 51.9% |
| 2025-05-08 | 404,370 | 0 | 545,783 | 74.1% |
| 2025-05-07 | 795,342 | 101,092 | 1,310,167 | 60.7% |
| 2025-05-06 | 549,987 | 25,721 | 1,067,309 | 51.5% |
| 2025-05-05 | 622,310 | 7,999 | 1,050,036 | 59.3% |
| 2025-05-02 | 2,688,135 | 21,747 | 4,851,253 | 55.4% |
| 2025-05-01 | 118,733 | 0 | 232,981 | 51.0% |
| 2025-04-30 | 227,438 | 0 | 422,654 | 53.8% |
| 2025-04-29 | 109,487 | 0 | 240,675 | 45.5% |
| 2025-04-28 | 42,462 | 0 | 93,916 | 45.2% |
| 2025-04-25 | 48,508 | 0 | 148,043 | 32.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy